Key facts
- It has raised $47.5M; the latest was Later Stage VC ($14.1M) in Dec 2024.
- Notable investors include KB Investment, Mayo Clinic, Yuanta Investment, Shinhan Securities, IBK Securities — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for LISCure Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for LISCure Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LISCure Biosciences
Developer of bacteria-mediated immunotherapy designed to treat tumors as well as cancer. The company's immunotherapy is used by combining drugs, consisting of seven pipelines of medicine and two pipelines of health-functioning food, enabling healthcare professionals to treat tumors as well as degenerative neurological, autoimmune and metabolic diseases.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2018
- Employees
- 30
- Website
- liscure.bio/
- Ownership
- Privately Held (backing)
LISCure Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LISCure Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LISCure Biosciences in its N-PORT filings yet. We sweep new filings monthly.